Carbon Medical Technologies — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Carbon Medical Technologies is a commercial-stage private company specializing in medical devices enhanced by a unique pyrolytic carbon coating. Its core technology platform provides exceptional biocompatibility and durability for permanent implants, with current products targeting radiation oncology, breast surgery, and urology. The company has established a global commercial footprint, distributing its products to 43 countries, and leverages its proprietary coating process to customize solutions for specific clinical applications. CMT operates as a product-focused business within the broader medical device sector.

OncologyUrologySurgery

Technology Platform

Proprietary pyrolytic carbon-coating process via chemical vapor deposition (CVD). This creates a hard, biocompatible, thromboresistant, and imaging-compatible coating for permanent medical implants, enabling customization for various applications.

Opportunities

The growing global adoption of precise, image-guided radiation therapy and increasing cancer incidence drive demand for high-performance fiducial markers.

Furthermore, the proven biocompatibility of the pyrolytic carbon platform presents significant white-space opportunities to develop new implantable devices for orthopedic, cardiovascular, and other surgical applications.

Risk Factors

Revenue is concentrated in a few product lines, primarily in oncology, making the business vulnerable to shifts in clinical practice or reimbursement.

Competition from larger medical device companies with greater resources poses a constant threat, and the company faces ongoing regulatory and quality control risks inherent to global medical device manufacturing.

Competitive Landscape

CMT competes in niche segments of the broader medical device market. For fiducial markers, competitors include large radiotherapy companies (e.g., Varian, Elekta) and specialized device firms. In urology, it competes with other bulking agent manufacturers and providers of alternative SUI procedures. Its primary competitive moat is its proprietary pyrolytic carbon coating, which offers distinct material advantages.

More companies in Drug Delivery & Formulation →More companies in United States →